ACE2 and COVID-19: Individuals with Delta breakthroughs (2 × COVID-19 vaccines) started out with lower levels of cross-reactive plasma antibodies against the Delta variant RBD (29% median RBD-ACE2 inhibition) early in infection (Figure 6A and Supplemental Figure 11A).